Ventzi Vassilev is a development lead for chronic Hepatitis B immunotherapies at GlaxoSmithKline Vaccines.
His initial education includes MS in genetic engineering (1989) from Sofia State University, Sofia, Bulgaria, followed by higher degree - PhD in molecular biology and virology (1993) from NRIGS, Moscow, Russia.
Dr. Vassilev extended his molecular virology training during a post–doctoral program at University of Nebraska – Lincoln, USA, where in 1998 assumed a faculty position.Dr Vassilev joined GSK in 2002 as responsible for molecular biology of viral vaccines. His team was involved in early development of number of new vaccines such as Cervarix, Shingrix, Havrix, Rotarix, Priorix and others. He led the integration of key new technologies enabling current development of novel class therapeutic vaccines.
In 2012 Dr. Vassilev assumed a position in the development part of the GSK organization, land led the development of HCV vaccines and new generation Flu vaccines.In 2017, he was appointed as lead of the chronic HBV immunotherapy early development, which is currently in Ph2 stage with mono- combination therapies being evaluated.Dr. Vassilev has multiple publications in peer-reviewed journals. He is a member of a number of professional associations.
